Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial
Concurrent radioimmunotherapy consisting of nivolumab and radiotherapy showed promising efficacy with a manageable safety profile in patients with metastatic mucosal melanoma, warranting further evaluation in large studies.
Authors
- Tomoya Yokota (ORCID: https://orcid.org/0000-0001-7327-7949)
- Manabu Muto (ORCID: https://orcid.org/0000-0002-3127-8203)
- Michio Yoshimura (ORCID: https://orcid.org/0000-0001-6665-2245)
- Hideki Ishikawa (ORCID: https://orcid.org/0000-0001-5980-698X)
- Shogen Boku (ORCID: https://orcid.org/0000-0002-5015-0379)
- Motoo Nomura (ORCID: https://orcid.org/0000-0002-5967-0610)
- Isao Oze (ORCID: https://orcid.org/0000-0002-0762-1147)
Institutions
- Kansai Medical University (JP)
- Kyoto University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka Cancer Center (JP)
- Aichi Cancer Center (JP)
- Kyoto University Hospital (JP)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.iotech.2025.101550
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00